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Abstract 
 
Background 
Drug-drug interactions (DDIs) can negatively affect pharmacotherapy. However pediatric 
DDI-studies are scarce. We undertook an exploratory study to investigate prevalence and 
clinical relevance of DDIs between cytostatic and non-cytostatic drugs in outpatient pediatric 
oncology patients.  
Procedure 
After informed consent and inclusion, the following information was collected: currently 
prescribed non-cytostatic and cytostatic drugs, comorbidities and use of over-the-counter 
(OTC) drugs, complementary and alternative medicines (CAM) and dietary supplements. All 
medication was screened for DDIs according to two databases: Micromedex
®
 Solutions and 
the Dutch drug database G-Standard. The researcher presented DDIs with an associated 
potential for adverse outcome and a proposal for intervention to three independent experts. If 
the experts considered a DDI to be potentially clinically relevant and requiring intervention, 
the physician was notified.  
Results 
Seventy-three patients were included (median age 8.9 years). A total of 67 different DDIs 
were counted (66 in Micromedex
®
 Solutions, 14 in G-standard and 13 DDIs in both 
databases). The medication reviews resulted in 35 interventions related to 11 different DDIs. 
The majority of DDIs concerned non-cytostatic drugs (25/35) and one third occurred between 
cytostatic and non-cytostatic drugs (10/35).  The use of QTc-interval prolonging drugs 
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resulted in one intervention. The use of OTC drugs, CAM or dietary supplements did not lead 
to DDIs.  
 
Conclusions 
This study resulted in a selection of 11 potentially clinically relevant DDIs for 73 outpatients 
in our pediatric oncology department. Interventions were formulated in close collaboration 
between physicians and clinical pharmacists. Future research should focus on assessing DDIs 
concerning QTc-interval prolongation.  
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Introduction 
The pharmacotherapeutic treatment of cancer patients is often associated with multiple side-
effects. In addition, a combination of drugs may result in drug-drug interactions (DDIs) 
which can adversely impact drug/treatment efficacy, lead to (serious) side-effects or even 
life-threatening events 
1
.  Of all adverse reactions related to pharmacotherapy in adults, it is 
estimated that 20-30% are DDIs 
1
. Moreover, the risk of a DDI due to the concomitant use of 
two drugs is approximately 6% and this risk increases exponentially with the number of 
prescribed drugs 
2
.  
 
In our hospital, cytostatic drugs are electronically prescribed in a prescribing system different 
from, and not linked to the prescribing system used for non-cytostatic drugs. As a result, there 
is no automatic check for DDIs between these drugs and consequently no DDI alert for the 
prescriber. The majority of research on DDIs has been conducted in adult oncology patients 
3-
8
 and pediatric DDI research in this area is scarce 
9
. It is possible that pediatric patients react 
differently from adults to drugs or to drug combinations which (in part) could be explained 
for by age-related developmental differences in body composition and organ function thus 
affecting drug pharmacokinetics, pharmacodynamics, or both 
10
. We therefore undertook an 
exploratory, prospective study to investigate the prevalence and clinical relevance of DDIs 
between cytostatic and non-cytostatic drugs (including over-the-counter (OTC) drugs, 
complementary and alternative medicines (CAM) and dietary supplements) in outpatient 
pediatric oncology patients.  
 
Methods 
A prospective, observational and descriptive a study was performed during a 4 month period 
(November 2014 – February 2015) at the Department of Pediatric Hematology-Oncology of 
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Erasmus MC-Sophia. Patients were randomly approached without regard to diagnosis, 
planned treatment schedule or responsible physician. After informed consent and inclusion, 
the following information was collected: list of currently prescribed non-cytostatic drugs 
(from community pharmacy & hospital prescribing system) and prescribed cytostatic drugs 
for the next 3 months (from hospital oncology prescribing system). Via a structured oral 
interview, the medication overviews were verified and specific patient related information, 
such as comorbidities and use of OTC drugs, CAM and dietary supplements was obtained.  
 
The study population consisted of outpatients younger than 18 years treated with cytostatic 
drugs at the pediatric oncology ward of an academic children’s hospital, Erasmus MC-Sophia 
in Rotterdam. The outpatient setting was selected because this is a population at risk for 
incomplete medication overviews 
4
,  thus limiting a complete medication review by the 
pharmacy. Patients were included after obtaining written informed consent from both parents 
or guardians and also from the patient himself older than 12 years. Patients were excluded in 
case of insufficient knowledge of the Dutch or English language and if it was not possible to 
obtain a list of currently prescribed drugs or to conduct a structured oral interview. 
 
Micromedex® Solutions and the Dutch drug database G-standard 
11,12
 were used to screen 
and assess DDIs as such, making use of both an international and national database. 
Additional information required to optimally assess potential DDIs was extracted from the 
hospital information system. Per patient the DDIs, and when applicable proposed 
interventions, were presented to a committee of 3 independent experts (hospital pharmacist, 
internist-clinical pharmacologist, resident in internal medicine) by the researcher. Feedback 
from each expert was independently submitted back to the researcher. If there was 
inconsistency in the feedback the independent experts were asked to reach a consensus, upon 
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which the identified DDI requiring an intervention was considered to be clinically relevant. 
The (hemato)oncologist in charge of the patient was advised how to manage this DDI.   
 
Results 
During the study period a total of 83 patients were randomly approached of which 73 were 
included (88%). Ten patients declined participation, mostly because they already participated 
in other studies. All patients included were treated with a curative intent. The main patient 
characteristics are summarized in Table 1.  
 
Potential drug-drug interactions 
Based on Micromedex
®
 Solutions and the G-standard database a total of 67 different DDIs 
were identified; 66 DDIs were documented in Micromedex® Solutions, 14 DDIs in the G-
Standard database and 13 DDIs were found in both databases.  The DDIs of all patients 
summed up to a total of 432 (359 in Micromedex® Solutions, 73 in the G-standard database; 
Table 2), with a median of 5 DDIs per patient (range 0 – 28). Our patients used a median of 5 
drugs (range 2 - 16) concomitant to the (standard) drugs prescribed in the cytostatic treatment 
course and concomitant to any OTC drugs, CAM or dietary supplements. In our study 83.5% 
of the patients were exposed to at least one DDI. The majority of DDIs were classified in the 
category ‘major severity’ which we could attribute to the interaction between co-trimoxazole 
and MTX, dose unspecified. However, as discussed further on only high and intermediate 
dose MTX required an intervention.  Of note, 84 QTc-interval prolonging interactions were 
counted by Micromedex® Solutions whereas the G-standard database counted none. An 
overview of the QTc-interval prolonging drugs prescribed in our population is shown in 
Table 3. 
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Interventions 
The medication reviews resulted in 35 interventions on 11 different DDIs (Table 4). Most 
interventions concerned interactions between non-cytostatic drugs (25 out of 35) and 10 
interventions were related to an interaction between a cytostatic and a non-cytostatic drug. 
13
 
DDIs needing interventions mainly concerned the following (number of interventions in 
parenthesis): prophylactic oral ciprofloxacin in combination with  magnesium gluconate (1), 
levothyroxin (1), dexamethasone (10) or prednisolone (13); MTX (high/intermediate dose) in 
combination with pneumocystis pneumonia prophylactic co-trimoxazole (2); vincristine in 
combination with itraconazole (2), voriconazole (1), aprepitant (3) or filgrastim (1) and a 
combination of 3 QTc-interval prolonging drugs: azithromycin, granisetron and crizotinib (1).  
 
Over-the-counter (OTC) drugs  - CAM - Dietary supplements  
In our study, patients used a median of 1.9 OTC drugs (range 0 – 8). The following OTC 
drugs, CAM and dietary supplements were found (number of patients in parenthesis): 
acetaminophen (68), multivitamins (13), vitamin D (9), melatonin (5), fishoil (2),  
magnesium (1), other (45). In the Netherlands the use of vitamin D supplements is advised 
for children under 4 years old 
14
, which explains the majority of the users in the study 
population (7 out of 9 patients). No DDIs were found with OTC medication, CAM or with 
dietary supplements. 
One patient used cannabidiol oil for pain relief and for anti-emetic reasons, However, this 
was not dispensed upon a prescription complying with the Dutch Opium Act, but purchased 
through an illegal distributor. Since 2001 the Office of Medicinal Cannabis (OMC) is the 
Dutch government agency responsible for the production and distribution of legal cannabis 
for medical purposes. There is currently one pharmacy in the Netherlands which prepares and 
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dispenses medicinal cannabis oil from the medicinal cannabis of the OMC. All other 
cannabis, in whatever form is illegal in the Netherlands. 
 
Discussion 
To our knowledge this study is the first to assess the prevalence of clinically relevant DDIs 
among outpatient pediatric cancer patients in combination with specific interventions and 
advice on how to manage the determined DDI. The majority of DDIs concerned non-
cytostatic drugs (25/35) and one third occurred between cytostatic and non-cytostatic drugs 
(10/35). The use of OTC medication, CAM or dietary supplements was low and did not lead 
to DDIs. Close collaboration between physicians, clinical pharmacologists and pharmacists 
resulted in a well-defined selection of 11 clinically relevant DDIs. There are several reasons 
why we strongly advise this collaboration to be continued, also outside the setting of a 
clinical trial; in many hospitals there is (still) no automatic / electronic drug interaction alert 
between cytostatic and non-cytostatic drugs and as such prescribers must rely on DDI 
references and their proposed interventions which are often inconsistent. In addition, close 
interdisciplinary collaboration also increases the awareness for potentially clinically relevant 
DDIs and may help to reduce alert fatigue, an important issue in DDI clinical decision 
support 
15
. We anticipate several issues which can impact on the occurrence of DDIs in 
pediatric oncology such as an increase in the use of tyrosine-kinase inhibitors, known to 
result in clinically relevant DDIs 
16
 and more use of complementary and alternative 
medications (CAM), also known to be involved in PK/PD interactions with 
chemotherapeutics 
17
, yet freely available via the internet and often of inferior pharmaceutical 
quality. The approach of our study has several strengths. There were no restrictions based on 
tumor type regarding inclusion of patients, which resulted in a varied, yet representative 
population. Furthermore, we used a national (G-standard) and an international (Micromedex
®
 
  
 
This article is protected by copyright. All rights reserved. 
9 
 
Solutions) DDI database, both widely used in clinical practice. A limitation of this study is 
that patients were not followed over time to monitor the outcome of the proposed 
interventions. 
Several of the DDIs we found require a short discussion here. The combination of co-
trimoxazole and MTX results in increased MTX toxicity involving reduced folate 
metabolism, synergistic nephrotoxicity and reduced MTX clearance 
18
. Indeed, Micromedex
®
 
Solutions and G-standard both classify this DDI as ‘major’ and advise to avoid the 
combination of MTX (dose unspecified) and co-trimoxazole. This explains the high rate of 
major DDIs found in our study (Table 2). However, we only proposed an intervention for 
high dose MTX (defined as ≥ 500 mg/m2) and intermediate dose MTX (defined as 200-500 
mg/m
2
); co-trimoxazole was discontinued from 48 hours prior to 7 days after MTX infusion, 
according to the Dutch Childhood Oncology Group (DCOG) supportive care guidelines 
19
. 
The majority of cases classified as ‘major’ DDI required no intervention as the MTX dose 
was low or the co-trimoxazole already discontinued. Interestingly, recent research found no 
evidence for an interaction between high dose MTX (2,5 g/m
2
 or 5 g/m
2
) and prophylactic co-
trimoxazole 
20
. Notably, Brandalise et al implemented the same precautions (leucovorin, 
hydratation, alkalization) for 3-weekly MTX 200 mg/m2 MTX  as for HD-MTX 
21
. Given the 
most recent data from Watts et al 20 our current advice may require a revision.   
Ciprofloxacin is used for prophylaxis of bacterial infections during neutropenia 
19,22
,  
sometimes referred to as selective decontamination of the digestive tract, SDD (although 
ciprofloxacin is also absorbed into the systemic circulation). Magnesium salts cause a 
decrease in ciprofloxacin absorption by 20% to 80% due to chelation in the gut lumen and the 
same occurs with calcium salts, although to a lesser extent 
23
. An intake schedule in which 
ciprofloxacin is administered at least 4 hours before a magnesium salt is routinely advised 
11,23
. Interestingly, the DCOG guidelines do not advise an interval for co-administration with 
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milk products or tube feeds stating that ciprofloxacin is used prophylactically and that tube 
feeds are often already stopped for other, more compelling reasons making it difficult to 
achieve the target intake per day 
19
.  However, the most important reason is that clinical 
experience has demonstrated that rectal SDD swabs are negative, implying that the amount of 
ciprofloxacin available in the gut lumen is still sufficient despite the chelation interaction. 
In adults, the use of ciprofloxacin can cause pain around an affected tendon or lead to a 
complete tendon rupture. Corticosteroids may potentiate this side-effect 
24
. In our study 
approximately one third of the patients (23/73) were prescribed a combination of 
ciprofloxacin with either prednisolone or dexamethasone. Although no pediatric research has 
been performed and tendinopathy is mostly reported in middle-aged individuals, the DDI was 
reported to the responsible hemato-oncologist given the severity of the outcome 
25
.  
In the case of the DDI between vincristine and azole antifungals it is advised to avoid 
concomitant use by stopping the azole temporarily to prevent peripheral neuropathy 
26,27
, 
although there is no consensus about the length of this azole-free period 
19,28
. This is an issue 
which requires further research. 
The interaction between vincristine and aprepitant is based on moderate CYP3A4 inhibition 
by aprepitant 
29
. Since this DDI could have severe implications the review committee advised 
to monitor neurotoxicity. Vincristine is associated with minimal emetic risk 
30
 and therefore 
aprepitant is always initiated to mitigate the emetogenic potential of another cytostatic drug 
in the treatment schedule. In children already experiencing vincristine-induced neurotoxicity 
one could consider administering vincristine 48 hours later, thereby preventing the DDI. We 
anticipate an increase in pediatric aprepitant use now that the suspension has become and 
physicians should be aware of this DDI 
31
. 
In our study two patients who used several QTc-interval prolonging drugs 
32
 required a more 
detailed review. The G-standard database advises to avoid administration of two or more 
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drugs from the list ‘Drugs with known Torsade de Pointes (TdP) risk’ by CredibleMeds® 33 
and if concomitant use is unavoidable the physician should monitor the ECG 
33
. 
Micromedex
®
 Solutions gives a similar advice but does not classify QTc-interval prolonging 
drugs in risk categories, which explains the difference in found DDIs (84 QTc-interval 
prolonging DDIs in Micromedex
®
 Solutions vs 0 in G-standard database). In the first patient 
5 different QTc-interval prolonging drugs were prescribed: 2 drugs with ‘Known risk of 
TdP’, 2 with ‘Possible risk of TdP’ and 1 with ‘Conditional risk of TdP’ (Table 4). As one of 
the 2 ‘Known risk of TdP’ drugs was prescribed as ‘on demand’, this DDI was assessed to be 
not clinically relevant and no intervention was proposed 
33
. The second patient was 
prescribed 3 QTc-interval prolonging drugs of which 1 on the list ‘Known risk of TdP’ and 2 
on the list ‘Possible risk of TdP’. There are currently no guidelines that propose interventions 
upon administration of a combination of QTc-interval prolonging drugs from different lists of 
CredibleMeds
®
. However, given the severity of the possible side-effect we advised to 
monitor the ECG in the case of 1 ‘Known risk of TdP’ and 2 ‘Possible risk of TdP’ drugs 
(excluding ‘as needed’ drugs).  It is important to note that this intervention has not been 
validated and requires further research. 
One intervention describes the concurrent use of vincristine and filgrastim, which has been 
associated with an increase in peripheral neuropathy 
34
. A higher cumulative vincristine dose 
could increase the chance of neurotoxicity. Since the consequences can be serious, physicians 
were informed.  
Research on the use of OTC drugs in the pediatric oncology population is scarce 
35
. However, 
research in adults showed that 80% of the patients use OTC drugs, which in 10% of the cases 
results in a DDI 
4
. In our study the use of OTC drugs, CAM and dietary supplements did not 
result in DDIs, possibly due to the proactive policy the physicians pursue concerning those 
  
 
This article is protected by copyright. All rights reserved. 
12 
 
drugs: patients are strongly advised not to use any medication other than the anti-cancer 
treatment without first consulting their physician.   
In conclusion, this study gives insight in the prevalence and clinical relevance of DDIs in 
this specific population. Research on DDIs in the pediatric population is limited and most 
studies have small study populations. We strongly advise hemato-oncologists, clinical 
pharmacologists and pharmacists to collaborate in identifying and managing the discussed 
DDIs. Currently there is no clear guideline on assessing DDIs concerning multiple QTc-
interval prolonging drugs. This subject should be a focus for future research.  
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Table 1: Patient characteristics 
Variable Patients (n = 73) 
Age (years)   
Median (range) 8,9 (0,5 - 17,5) 
Sex   
Male 42 58% 
Female 31  
Type of malignancy   
Solid tumors 
27 37% 
Brain tumors   
- Low-grade glioma 3 4% 
- High-grade glioma 1 1% 
- Medulloblastoma 7 10% 
Other   
- Neuroblastoma 4 5% 
- Hepatoblastoma 1 1% 
- Nephroblastoma 2 3% 
- Rhabdomyosarcoma 7 10% 
- Ewing sarcoma 2 3% 
Hematological tumors 46 63% 
ALL 39 53% 
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Table 2: Classification of levels of severity in Micromedex Solutions
®
 and G-standard database 
Micromedex
®
 Solutions  
Level of 
severity 
DDIs 
(n) 
DDIs 
(%) 
Description 
Minor 11 3.1 The DDI would have limited clinical effects. Manifestations may 
include an increase in the frequency or severity of the side effects but 
generally would not require a major alteration therapy 
Moderate 96 26.7 The DDI may result in exacerbation of the patient’s condition and/or 
require an alteration therapy 
Major 252 70.2 The DDI may be life-threatening and/or require medical intervention 
to minimize or prevent serious adverse effects 
Contraindicated 0 0 The drugs are contraindicated for concurrent use. 
Unknown 0 0 Unknown 
Total 359 100%  
    
G-standard database
 
Level of 
severity 
DDIs 
(n) 
DDIs 
(%) 
Description 
A 2 3.0 Clinically insignificant or no effect 
B 0 0 Short-term discomfort (<24-48 h) without sequelae 
C 6 9.1 Long-term discomfort (48-168 h) without sequelae 
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Table 3: QTc-interval prolonging drugs in the studied population 
Known risk Possible risk Conditional risk 
Azithromycin Crizotinib Amitryptiline 
Ciprofloxacin Dasatinib Itraconazole 
Fluconazole Granisetron Voriconazole 
Ondansetron   
Classification according to CredibleMeds
®
 Database 
33
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Table 4: Interventions on DDIs   
Drug 
(victim) 
Route Drug 
(perpetrator) 
Route N
a 
PK/ 
PD
b 
Effect DDI Intervention Intervention 
according to 
Hansten & 
Horn’s 13 
Severity/documentation 
Micromedex
®
 
Solutions 
G-
standard
c
 
Ciprofloxacin p.o. Magnesium 
gluconate 
p.o. 1 PK 20-80% 
decreased 
ciprofloxacin  
Interval 
schedule;  
administer 
ciprofloxacin 
at least 4 
hours before 
magnesium 
Interval 
schedule, 
monitor 
response 
Moderate, 
good 
C3 
Levothyroxin p.o. Ciprofloxacin p.o. 1 PK 39% 
decreased 
AUC of 
levothyroxine   
Interval 
schedule; 
administer 
ciprofloxacin 
2 hours after 
levothyroxine 
Interval 
schedule (6 
hours) and 
monitor 
Moderate, 
good 
N/A 
MTX (HD) i.v. Co-trimoxazole All 1 PK Increased risk 
of MTX 
toxicity 
Stop co-
trimoxazole 
48 hours 
before and 7 
days after the 
MTX 
infusion 
 
Choose other 
antibiotic 
treatment 
Major, 
excellent 
F3 
MTX 
(intermediate) 
i.v. Co-trimoxazole All 1 PK Major, 
excellent 
F3  
Vincristine i.v. Itraconazole All 2 PK Increased 
vincristine 
plasma levels 
due to 
Vincristine 
q3wk: stop 
azole 3 days 
in advance till 
Consider 
other 
antifungal 
treatment 
Major, 
excellent 
E2 
 
